

LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINCIC, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.

LISA DIROCCO TYNER
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
THEODORE R. WEST
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.

* Admitted in TX only
** Admitted in CT only

February 3, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/615158
For: *EPA AND DHA ENRICHED OMEGA-3 SUPPLEMENT FOR THE
TREATMENT OF DRYE EYE MEIDOMIANITIS AND XEROSTIMIA*
Inventor: Gilbard, Jeffrey P.
Filed: July 7, 2003
Our Ref. No.: AVR-005

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB/08;
3. Copies of publications cited in PTO Form SB/08 (8); and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on:


February 3, 2004

Date

Ralph A. Loren, Reg. No. 29,325

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Ralph A. Loren
Registration No. 29,325
Attorney for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Gilbard, Jeffrey P.

Serial No.: 10/615158

Filed: July 7, 2003

For: *EPA AND DHA ENRICHED OMEGA-3
SUPPLEMENT FOR THE TREATMENT OF DRY
EYE MEIDOMIANITIS AND XEROSTOMIA*

Attorney Docket No.: AVR-005

Group Art Unit: 1614

Examiner: Not Yet Assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

February 3, 2004

Date of Signature and of Mail Deposit

By:


Ralph A. Loren
Registration No. 29,325
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicant and his Attorney are aware of the following publications and information, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR   1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR  1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP




Ralph A. Loren
Registration No. 29,325
Attorney for Applicant

28 State Street
Boston, MA 02109
(617) 227-7400

Date: February 3, 2004

RAL/krij
Enclosures



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/615158
				Filing Date	July 7, 2003
				First Named Inventor	Gilbard, Jeffrey P.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AVR-005

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A1	Akbar, M. <i>et al.</i> "Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway." <i>Journal of Neurochemistry</i> 82:655-665 (2002).	
	A2	Caughey, G.E. <i>et al.</i> "The effect on human tumor necrosis factor α and interleukin 1 β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil." <i>Am. J. Clin. Nutr.</i> 63:116-22 (1996).	
	A3	Curtis, C.L. <i>et al.</i> "n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation." <i>The Journal of Biological Chemistry</i> 275(2):721-724 (2000).	
	A4	Kishida, E. <i>et al.</i> "Distinctive inhibitory activity of docosahexaenoic acid against sphingosine-induced apoptosis." <i>Biochimica et Biophysica Acta</i> 1391:401-408 (1998).	
	A5	Kronemyer, B. "Dry eye successfully treated with oral flaxseed oil." <i>Ocular Surgery News EUROPE/ASIA-PACIFIC EDITION</i> retrieved from the internet at http://www.osnsupersite.com/default.asp?ID=390 2pp. (2000).	
	A6	Oxholm, P. <i>et al.</i> "Essential fatty acid status in cell membranes and plasma of patients with primary Sjögren's syndrome." <i>Prostaglandins, Lukotrienes and Essential Fatty Acids</i> 59(4):239-245 (1998).	
	A7	Sullivan, B.D. <i>et al.</i> "Correlations between nutrient intake and the polar lipid profiles of meibomian gland secretions in women with Sjögren's syndrome." in <i>Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3</i> edited by Sullivan, D. <i>et al.</i> , Kluwer Academic/Plenum Publishers pp.441-447 (2002).	
	A8	Yano, M. <i>et al.</i> "Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor." <i>J. Nutr.</i> 130(5):1095-1101 (2000).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--